![Nigel Crockett](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Nigel Crockett
Plus aucun poste en cours
Fortune : 210 849 $ au 31/08/2026
Profil
Nigel Crockett is the founder of Tukan Partners Ltd. (2005).
Former positions include Chairman-Business Development Working Group at The Bioindustry Association, Director at Nxera Pharma UK Ltd., Board Member & Commercial Director at Procarta Biosystems Ltd. (2010-2012), Vice President-Business Development at Astex Therapeutics Ltd., Head-Business Development at Crescendo Biologics Ltd., and Chief Business Officer at Bicycle Therapeutics Plc (2019-2025).
Education includes an undergraduate degree from The University of Manchester (1986) and a doctorate from the University of Cambridge (1989).
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 03/01/2025 | 51 053 ( 0,13 % ) | 210 849 $ | 31/08/2026 |
Anciens postes connus de Nigel Crockett
| Sociétés | Poste | Fin |
|---|---|---|
| BICYCLE THERAPEUTICS PLC | Corporate Officer/Principal | 27/03/2025 |
Tukan Partners Ltd. | Fondateur | 01/02/2021 |
The Bioindustry Association
 The Bioindustry Association Miscellaneous Commercial ServicesCommercial Services Operates as a association to encourage and promote bioscience sector | Corporate Officer/Principal | - |
Crescendo Biologics Ltd.
 Crescendo Biologics Ltd. Miscellaneous Commercial ServicesCommercial Services Engages in the development of new medicines based on antibody fragment technology | Corporate Officer/Principal | - |
Nxera Pharma UK Ltd.
 Nxera Pharma UK Ltd. Pharmaceuticals: MajorHealth Technology Designs and develops new medicines targeting G protein-coupled receptors | Directeur/Membre du Conseil | - |
Formation de Nigel Crockett
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
82
Relations au 1er degré
9
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 9 |
|---|---|
The University of Manchester
 The University of Manchester Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Cambridge
 University of Cambridge Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Astex Therapeutics Ltd.
 Astex Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Discovers and develops fragment based drug | Health Technology |
Nxera Pharma UK Ltd.
Nxera Pharma UK Ltd. Pharmaceuticals: MajorHealth Technology Designs and develops new medicines targeting G protein-coupled receptors | Health Technology |
The Bioindustry Association
The Bioindustry Association Miscellaneous Commercial ServicesCommercial Services Operates as a association to encourage and promote bioscience sector | Commercial Services |
Procarta Biosystems Ltd.
 Procarta Biosystems Ltd. Pharmaceuticals: MajorHealth Technology Develops deoxyribonucleic acid based therapeuticals and antibacterials | Health Technology |
Bicycle Therapeutics Plc
 Bicycle Therapeutics Plc Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops molecules and oncology medicines | Health Technology |
Crescendo Biologics Ltd.
Crescendo Biologics Ltd. Miscellaneous Commercial ServicesCommercial Services Engages in the development of new medicines based on antibody fragment technology | Commercial Services |
Tukan Partners Ltd. |
